A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects With Metastatic or Locally-advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2018
At a glance
- Drugs STI-A1015 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 21 Aug 2018 Status changed from planning to recruiting.
- 09 Feb 2018 New trial record
- 05 Feb 2018 According to a Sorrento Therapeutics media release, the company is planning to conduct Phase 1 studies at two clinical sites in South Korea, namely, Seoul National University Hospital (SNUH) and Samsung Medical Center (SMC).